^
    Back
    Association details:
    Biomarker:ARID1A mutation
    Cancer:Ovarian Cancer
    Drug:tulmimetostat (CPI-0209) (EZH2 inhibitor, EZH1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas

    Excerpt:
    ...- Known ARID1A mutation (NGS testing)...
    Trial ID:
    FIH
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    IGCS 2023
    Title:

    EZH2/EZH1 INHIBITOR TULMIMETOSTAT (CPI-0209): PRELIMINARY PHASE II RESULTS AND FIRST BIOMARKER FINDINGS IN PATIENTS WITH ARID1A-MUTANT OVARIAN CLEAR CELL OR ENDOMETRIAL CARCINOMAS (OCCC/EC)

    Published date:
    10/18/2023
    Excerpt:
    The Phase II study is evaluating tulmimetostat 350 mg once daily in 6 disease-based cohorts, including ARID1Amut OCCC/EC….Both cohorts are eligible for Stage 2 expansion, with 1 and 2 confirmed partial responses in patients with OCCC and EC, respectively (Table)....These preliminary findings in heavily pre-treated patients with ARID1Amut OCCC/EC support continued investigation of tulmimetostat monotherapy.
    Trial ID:
    FIH